{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,4]],"date-time":"2026-06-04T15:14:33Z","timestamp":1780586073261,"version":"3.54.1"},"reference-count":40,"publisher":"Springer Science and Business Media LLC","issue":"6","license":[{"start":{"date-parts":[[2026,4,2]],"date-time":"2026-04-02T00:00:00Z","timestamp":1775088000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2026,4,2]],"date-time":"2026-04-02T00:00:00Z","timestamp":1775088000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"funder":[{"name":"Novartis Pharma AG, Basel, Switzerland"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Dermatol Ther (Heidelb)"],"published-print":{"date-parts":[[2026,6]]},"DOI":"10.1007\/s13555-026-01722-0","type":"journal-article","created":{"date-parts":[[2026,4,2]],"date-time":"2026-04-02T03:29:05Z","timestamp":1775100545000},"page":"2837-2856","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Retention, Effectiveness, and Safety of Secukinumab in Plaque Psoriasis: 5-Year Results from SERENA"],"prefix":"10.1007","volume":"16","author":[{"given":"Matthias","family":"Augustin","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paul-Gunther","family":"Sator","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ralph","family":"von Kiedrowski","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dimitris","family":"Rigopoulos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marco","family":"Romanelli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pierre-Dominique","family":"Ghislain","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tiago","family":"Torres","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dimitrios","family":"Ioannides","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cynthia","family":"Vizcaya","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andreas","family":"Clemens","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Weibin","family":"Bao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christelle C.","family":"Pieterse","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Barbara","family":"Schulz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Piotr","family":"Jagiello","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2547-3440","authenticated-orcid":false,"given":"Curdin","family":"Conrad","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,4,2]]},"reference":[{"issue":"10281","key":"1722_CR1","doi-asserted-by":"publisher","first-page":"1301","DOI":"10.1016\/S0140-6736(20)32549-6","volume":"397","author":"CEM Griffiths","year":"2021","unstructured":"Griffiths CEM, Armstrong AW, Gudjonsson JE, Barker JNWN. Psoriasis. Lancet. 2021;397(10281):1301\u201315.","journal-title":"Lancet"},{"issue":"9364","key":"1722_CR2","doi-asserted-by":"publisher","first-page":"1197","DOI":"10.1016\/S0140-6736(03)12954-6","volume":"361","author":"M Lebwohl","year":"2003","unstructured":"Lebwohl M. Psoriasis. Lancet. 2003;361(9364):1197\u2013204.","journal-title":"Lancet"},{"issue":"9583","key":"1722_CR3","doi-asserted-by":"publisher","first-page":"263","DOI":"10.1016\/S0140-6736(07)61128-3","volume":"370","author":"CEM Griffiths","year":"2007","unstructured":"Griffiths CEM, Barker JNWN. Pathogenesis and clinical features of psoriasis. Lancet. 2007;370(9583):263\u201371.","journal-title":"Lancet"},{"issue":"2","key":"1722_CR4","doi-asserted-by":"publisher","first-page":"271","DOI":"10.1067\/S0190-9622(03)01479-8","volume":"49","author":"AA Pettey","year":"2003","unstructured":"Pettey AA, Balkrishnan R, Rapp, Fleischer AB, Feldman SR. Patients with palmoplantar psoriasis have more physical disability and discomfort than patients with other forms of psoriasis: implications for clinical practice. J Am Acad Dermatol. 2003;49(2):271\u20135.","journal-title":"J Am Acad Dermatol"},{"key":"1722_CR5","first-page":"1","volume":"2","author":"MA Radtke","year":"2011","unstructured":"Radtke MA, Langenbruch AK, Sch\u00e4fer I, Herberger K, Reich K, Augustin M. Nail psoriasis as a severity indicator: results from the PsoReal study. Patient Relat Outcome Meas. 2011;2:1\u20136.","journal-title":"Patient Relat Outcome Meas"},{"issue":"4","key":"1722_CR6","doi-asserted-by":"publisher","first-page":"509","DOI":"10.1007\/s13555-018-0257-y","volume":"8","author":"KM Beck","year":"2018","unstructured":"Beck KM, Yang EJ, Sanchez IM, Liao W. Treatment of genital psoriasis: a systematic review. Dermatol Ther. 2018;8(4):509\u201325.","journal-title":"Dermatol Ther"},{"issue":"6","key":"1722_CR7","doi-asserted-by":"publisher","first-page":"978","DOI":"10.1016\/j.jaad.2015.02.1127","volume":"72","author":"C Ryan","year":"2015","unstructured":"Ryan C, Sadlier M, De Vol E, Patel M, Lloyd AA, Day A, et\u00a0al. Genital psoriasis is associated with significant impairment in quality of life and sexual functioning. J Am Acad Dermatol. 2015;72(6):978\u201383.","journal-title":"J Am Acad Dermatol"},{"issue":"6","key":"1722_CR8","doi-asserted-by":"publisher","first-page":"763","DOI":"10.1111\/jdv.12174","volume":"28","author":"A Bewley","year":"2014","unstructured":"Bewley A, Burrage BM, Ersser SJ, Hansen M, Ward C. Identifying individual psychosocial and adherence support needs in patients with psoriasis: a multinational two-stage qualitative and quantitative study. J Eur Acad Dermatol Venereol. 2014;28(6):763\u201370.","journal-title":"J Eur Acad Dermatol Venereol"},{"issue":"4","key":"1722_CR9","doi-asserted-by":"publisher","first-page":"729","DOI":"10.1111\/j.1365-2133.2006.07405.x","volume":"155","author":"L Dubertret","year":"2006","unstructured":"Dubertret L, Mrowietz U, Ranki A, van de Kerkhof PC, Chimenti S, Lotti T, et\u00a0al. European patient perspectives on the impact of psoriasis: the EUROPSO patient membership survey. Br J Dermatol. 2006;155(4):729\u201336.","journal-title":"Br J Dermatol"},{"issue":"5","key":"1722_CR10","doi-asserted-by":"publisher","first-page":"798","DOI":"10.1111\/jdv.13891","volume":"31","author":"P Fleming","year":"2017","unstructured":"Fleming P, Bai JW, Pratt M, Sibbald C, Lynde C, Gulliver WP. The prevalence of anxiety in patients with psoriasis: a systematic review of observational studies and clinical trials. J Eur Acad Dermatol Venereol. 2017;31(5):798\u2013807.","journal-title":"J Eur Acad Dermatol Venereol"},{"issue":"1","key":"1722_CR11","first-page":"67","volume":"92","author":"E Hrehor\u00f3w","year":"2011","unstructured":"Hrehor\u00f3w E, Salomon J, Matusiak \u0141, Reich A, Szepietowski JC. Patients with psoriasis feel stigmatized. Acta Derm Venereol. 2011;92(1):67\u201372.","journal-title":"Acta Derm Venereol"},{"issue":"8","key":"1722_CR12","doi-asserted-by":"publisher","first-page":"885","DOI":"10.1111\/j.1468-3083.2009.03537.x","volume":"24","author":"J Schmitt","year":"2010","unstructured":"Schmitt J, Ford DE. Psoriasis is independently associated with psychiatric morbidity and adverse cardiovascular risk factors, but not with cardiovascular events in a population-based sample. J Eur Acad Dermatol Venereol. 2010;24(8):885\u201392.","journal-title":"J Eur Acad Dermatol Venereol"},{"issue":"1","key":"1722_CR13","first-page":"15","volume":"17","author":"M Young","year":"2005","unstructured":"Young M. The psychological and social burdens of psoriasis. Dermatol Nurs. 2005;17(1):15\u20139.","journal-title":"Dermatol Nurs"},{"issue":"4","key":"1722_CR14","doi-asserted-by":"publisher","first-page":"654","DOI":"10.1016\/j.jaad.2012.08.015","volume":"68","author":"AW Armstrong","year":"2013","unstructured":"Armstrong AW, Harskamp CT, Armstrong EJ. Psoriasis and metabolic syndrome: a systematic review and meta-analysis of observational studies. J Am Acad Dermatol. 2013;68(4):654\u201362.","journal-title":"J Am Acad Dermatol"},{"issue":"4","key":"1722_CR15","doi-asserted-by":"publisher","first-page":"915","DOI":"10.1002\/art.39494","volume":"68","author":"L Eder","year":"2016","unstructured":"Eder L, Haddad A, Rosen CF, Lee KA, Chandran V, Cook R, et\u00a0al. The incidence and risk factors for psoriatic arthritis in patients with psoriasis: a prospective cohort study. Arthritis Rheumatol. 2016;68(4):915\u201323.","journal-title":"Arthritis Rheumatol"},{"issue":"14","key":"1722_CR16","doi-asserted-by":"publisher","first-page":"1735","DOI":"10.1001\/jama.296.14.1735","volume":"296","author":"JM Gelfand","year":"2006","unstructured":"Gelfand JM, Neimann AL, Shin DB, Wang X, Margolis DJ, Troxel AB. Risk of myocardial infarction in patients with psoriasis. JAMA. 2006;296(14):1735\u201341.","journal-title":"JAMA"},{"issue":"8","key":"1722_CR17","doi-asserted-by":"publisher","first-page":"1000","DOI":"10.1093\/eurheartj\/ehp567","volume":"31","author":"NN Mehta","year":"2009","unstructured":"Mehta NN, Azfar RS, Shin DB, Neimann AL, Troxel AB, Gelfand JM. Patients with severe psoriasis are at increased risk of cardiovascular mortality: cohort study using the General Practice Research Database. Eur Heart J. 2009;31(8):1000\u20136.","journal-title":"Eur Heart J"},{"issue":"2","key":"1722_CR18","doi-asserted-by":"publisher","first-page":"233","DOI":"10.1002\/art.24172","volume":"61","author":"FC Wilson","year":"2009","unstructured":"Wilson FC, Icen M, Crowson CS, McEvoy MT, Gabriel SE, Kremers HM. Incidence and clinical predictors of psoriatic arthritis in patients with psoriasis: a population-based study. Arthritis Rheum. 2009;61(2):233\u20139.","journal-title":"Arthritis Rheum"},{"issue":"3","key":"1722_CR19","doi-asserted-by":"publisher","first-page":"401","DOI":"10.1016\/S0190-9622(99)70112-X","volume":"41","author":"SR Rapp","year":"1999","unstructured":"Rapp SR, Feldman SR, Exum ML, Fleischer AB, Reboussin DM. Psoriasis causes as much disability as other major medical diseases. J Am Acad Dermatol. 1999;41(3):401\u20137.","journal-title":"J Am Acad Dermatol"},{"issue":"3","key":"1722_CR20","doi-asserted-by":"publisher","first-page":"425","DOI":"10.1016\/j.jaad.2017.05.019","volume":"77","author":"S Singh","year":"2017","unstructured":"Singh S, Taylor C, Kornmehl H, Armstrong AW. Psoriasis and suicidality: a systematic review and meta-analysis. J Am Acad Dermatol. 2017;77(3):425-440.e422.","journal-title":"J Am Acad Dermatol"},{"issue":"6","key":"1722_CR21","doi-asserted-by":"publisher","first-page":"1174","DOI":"10.1111\/jdv.16180","volume":"34","author":"M Augustin","year":"2020","unstructured":"Augustin M, Jullien D, Martin A, Peralta C. Real-world evidence of secukinumab in psoriasis treatment\u2014a meta-analysis of 43 studies. J Eur Acad Dermatol Venereol. 2020;34(6):1174\u201385.","journal-title":"J Eur Acad Dermatol Venereol"},{"issue":"4","key":"1722_CR22","doi-asserted-by":"publisher","first-page":"667","DOI":"10.1016\/j.jaad.2017.05.033","volume":"77","author":"J Bagel","year":"2017","unstructured":"Bagel J, Duffin KC, Moore A, Ferris LK, Siu K, Steadman J, et\u00a0al. The effect of secukinumab on moderate-to-severe scalp psoriasis: results of a 24-week, randomized, double-blind, placebo-controlled phase 3b study. J Am Acad Dermatol. 2017;77(4):667\u201374.","journal-title":"J Am Acad Dermatol"},{"issue":"9","key":"1722_CR23","doi-asserted-by":"publisher","first-page":"1507","DOI":"10.1111\/jdv.14878","volume":"32","author":"R Bissonnette","year":"2018","unstructured":"Bissonnette R, Luger T, Tha\u00e7i D, Toth D, Lacombe A, Xia S, et\u00a0al. Secukinumab demonstrates high sustained efficacy and a favourable safety profile in patients with moderate-to-severe psoriasis through 5 years of treatment (SCULPTURE Extension Study). J Eur Acad Dermatol Venereol. 2018;32(9):1507\u201314.","journal-title":"J Eur Acad Dermatol Venereol"},{"issue":"1","key":"1722_CR24","doi-asserted-by":"publisher","first-page":"111","DOI":"10.1186\/s13075-019-1882-2","volume":"21","author":"A Deodhar","year":"2019","unstructured":"Deodhar A, Mease P, McInnes IB, Baraliakos X, Reich K, Blauvelt A, et\u00a0al. Long-term safety of secukinumab in patients with moderate-to-severe plaque psoriasis, psoriatic arthritis, and ankylosing spondylitis: integrated pooled clinical trial and post-marketing surveillance data. Arthritis Res Ther. 2019;21(1):111.","journal-title":"Arthritis Res Ther"},{"issue":"1","key":"1722_CR25","doi-asserted-by":"publisher","first-page":"70","DOI":"10.1016\/j.jaad.2016.07.058","volume":"76","author":"A Gottlieb","year":"2017","unstructured":"Gottlieb A, Sullivan J, van Doorn M, Kubanov A, You R, Parneix A, et\u00a0al. Secukinumab shows significant efficacy in palmoplantar psoriasis: results from GESTURE, a randomized controlled trial. J Am Acad Dermatol. 2017;76(1):70\u201380.","journal-title":"J Am Acad Dermatol"},{"issue":"3","key":"1722_CR26","doi-asserted-by":"publisher","first-page":"750","DOI":"10.1016\/j.jaci.2019.04.029","volume":"144","author":"JG Krueger","year":"2019","unstructured":"Krueger JG, Wharton KA, Schlitt T, Suprun M, Torene RI, Jiang X, et\u00a0al. IL-17A inhibition by secukinumab induces early clinical, histopathologic, and molecular resolution of psoriasis. J Allergy Clin Immunol. 2019;144(3):750\u201363.","journal-title":"J Allergy Clin Immunol"},{"issue":"4","key":"1722_CR27","doi-asserted-by":"publisher","first-page":"326","DOI":"10.1056\/NEJMoa1314258","volume":"371","author":"RG Langley","year":"2014","unstructured":"Langley RG, Elewski BE, Lebwohl M, Reich K, Griffiths CEM, Papp K, et\u00a0al. Secukinumab in plaque psoriasis\u2014results of two phase 3 trials. N Engl J Med. 2014;371(4):326\u201338.","journal-title":"N Engl J Med"},{"issue":"suppl 2","key":"1722_CR28","doi-asserted-by":"publisher","first-page":"iii116","DOI":"10.1136\/annrheumdis-2012-202371","volume":"72","author":"DD Patel","year":"2013","unstructured":"Patel DD, Lee DM, Kolbinger F, Antoni C. Effect of IL-17A blockade with secukinumab in autoimmune diseases. Ann Rheum Dis. 2013;72(suppl 2):iii116.","journal-title":"Ann Rheum Dis"},{"issue":"5","key":"1722_CR29","doi-asserted-by":"publisher","first-page":"954","DOI":"10.1111\/bjd.17351","volume":"181","author":"K Reich","year":"2019","unstructured":"Reich K, Sullivan J, Arenberger P, Mrowietz U, Jazayeri S, Augustin M, et\u00a0al. Effect of secukinumab on the clinical activity and disease burden of nail psoriasis: 32-week results from the randomized placebo-controlled TRANSFIGURE trial. Br J Dermatol. 2019;181(5):954\u201366.","journal-title":"Br J Dermatol"},{"issue":"3","key":"1722_CR30","doi-asserted-by":"publisher","first-page":"729","DOI":"10.1007\/s13555-024-01122-2","volume":"14","author":"R Sun","year":"2024","unstructured":"Sun R, Bustamante M, Gurusamy VK, Lebwohl M, Gottlieb AB, Mease PJ, et\u00a0al. Safety of secukinumab from 1 million patient-years of exposure: experience from post-marketing setting and clinical trials. Dermatol Ther. 2024;14(3):729\u201343.","journal-title":"Dermatol Ther"},{"issue":"2","key":"1722_CR31","doi-asserted-by":"publisher","first-page":"198","DOI":"10.1093\/bjd\/ljac040","volume":"188","author":"RG Langley","year":"2022","unstructured":"Langley RG, Sofen S, Dei-Cas I, Reich K, Sigurgeirsson B, Warren RB, et\u00a0al. Secukinumab long-term efficacy and safety in psoriasis through to year 5 of treatment: results of a randomized extension of the phase III ERASURE and FIXTURE trials. Br J Dermatol. 2022;188(2):198\u2013207.","journal-title":"Br J Dermatol"},{"issue":"11","key":"1722_CR32","doi-asserted-by":"publisher","first-page":"1763","DOI":"10.1007\/s12325-018-0805-y","volume":"35","author":"L Blonde","year":"2018","unstructured":"Blonde L, Khunti K, Harris SB, Meizinger C, Skolnik NS. Interpretation and impact of real-world clinical data for the practicing clinician. Adv Ther. 2018;35(11):1763\u201374.","journal-title":"Adv Ther"},{"key":"1722_CR33","doi-asserted-by":"publisher","first-page":"295","DOI":"10.2147\/JMDH.S160029","volume":"11","author":"VB Katkade","year":"2018","unstructured":"Katkade VB, Sanders KN, Zou KH. Real world data: an opportunity to supplement existing evidence for the use of long-established medicines in health care decision making. J Multidiscip Healthc. 2018;11:295\u2013304.","journal-title":"J Multidiscip Healthc"},{"issue":"3","key":"1722_CR34","doi-asserted-by":"publisher","first-page":"rkad055","DOI":"10.1093\/rap\/rkad055","volume":"7","author":"K Gaffney","year":"2023","unstructured":"Gaffney K, Gullick N, MacKay K, Patel Y, Sengupta R, Sheeran T, et\u00a0al. Real-world evidence for secukinumab in UK patients with psoriatic arthritis or radiographic axial spondyloarthritis: interim 2-year analysis from SERENA. Rheumatol Adv Pract. 2023;7(3):rkad055.","journal-title":"Rheumatol Adv Pract."},{"issue":"6","key":"1722_CR35","doi-asserted-by":"publisher","first-page":"2865","DOI":"10.1007\/s12325-020-01352-8","volume":"37","author":"U Kiltz","year":"2020","unstructured":"Kiltz U, Sfikakis PP, Gaffney K, Sator PG, von Kiedrowski R, Bounas A, et\u00a0al. Secukinumab use in patients with moderate to severe psoriasis, psoriatic arthritis and ankylosing spondylitis in real-world setting in Europe: baseline data from SERENA study. Adv Ther. 2020;37(6):2865\u201383.","journal-title":"Adv Ther"},{"issue":"10","key":"1722_CR36","doi-asserted-by":"publisher","first-page":"1796","DOI":"10.1111\/jdv.18329","volume":"36","author":"M Augustin","year":"2022","unstructured":"Augustin M, Sator PG, von Kiedrowski R, Conrad C, Rigopoulos D, Romanelli M, et\u00a0al. Secukinumab demonstrated sustained retention, effectiveness and safety in a real-world setting in patients with moderate-to-severe plaque psoriasis: long-term results from an interim analysis of the SERENA study. J Eur Acad Dermatol Venereol. 2022;36(10):1796\u2013804.","journal-title":"J Eur Acad Dermatol Venereol"},{"issue":"5","key":"1722_CR37","doi-asserted-by":"publisher","first-page":"1004","DOI":"10.1111\/jdv.18846","volume":"37","author":"L Iversen","year":"2023","unstructured":"Iversen L, Conrad C, Eidsmo L, Costanzo A, Narbutt J, Pinter A, et\u00a0al. Secukinumab demonstrates superiority over narrow-band ultraviolet B phototherapy in new-onset moderate to severe plaque psoriasis patients: week 52 results from the STEPIn study. J Eur Acad Dermatol Venereol. 2023;37(5):1004\u201316.","journal-title":"J Eur Acad Dermatol Venereol"},{"issue":"5, Supplement","key":"1722_CR38","doi-asserted-by":"publisher","first-page":"S142","DOI":"10.1016\/j.jid.2023.03.838","volume":"143","author":"C Conrad","year":"2023","unstructured":"Conrad C, Gaulis S, Bier K, Gudjonsson J, Eidsmo L, K\u00e4rner J, et\u00a0al. 828 Early intervention with secukinumab may affect the establishment of tissue memory in psoriasis: results from a DNA methylation analysis. J Invest Dermatol. 2023;143(5, Supplement):S142.","journal-title":"J Invest Dermatol"},{"key":"1722_CR39","unstructured":"Mrowietz U, Coates LC, Tha\u00e7i D, Lebwohl M, Sigurgeirsson B, Warren RB, et\u00a0al. Long-term impact of secukinumab on the prevention of psoriatic arthritis in patients with psoriasis: a 5-year pooled analysis of the ERASURE, FIXTURE and SCULPTURE studies. Arthritis Rheumatol. 2025;77(S9)."},{"key":"1722_CR40","unstructured":"Armstrong A, Merola J, Wang G, Faucher A, Taiji R, Vekeman F, et\u00a0al. Comparison of incidence of psoriatic arthritis in patients with psoriasis treated with interleukin-17 Inhibitors vs interleukin-23 inhibitors, interleukin-12\/23 inhibitors, and tumor necrosis factor inhibitors in real-world practice: a retrospective study. Arthritis Rheumatol. 2025;77(S9)."}],"container-title":["Dermatology and Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s13555-026-01722-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s13555-026-01722-0","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s13555-026-01722-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,4]],"date-time":"2026-06-04T14:53:21Z","timestamp":1780584801000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s13555-026-01722-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4,2]]},"references-count":40,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2026,6]]}},"alternative-id":["1722"],"URL":"https:\/\/doi.org\/10.1007\/s13555-026-01722-0","relation":{},"ISSN":["2193-8210","2190-9172"],"issn-type":[{"value":"2193-8210","type":"print"},{"value":"2190-9172","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,4,2]]},"assertion":[{"value":"18 December 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 March 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 April 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Matthias Augustin has received consulting fees and\/or speaker fees and\/or institutional research support from the following pharmaceutical companies manufacturing drugs for psoriasis: AbbVie, Almirall, Amgen, Biogen, Boehringer, Bristol-Myers Squibb, Celgene, Celltrion, Centocor, Eli Lilly, Fresenius, GSK, Hexal, Janssen, Klinge, LEO Pharma, MC2, Medac, Merck, MSD, Mylan, Novartis, Pfizer, Sandoz, Sun Pharma, UCB, and Viatris. Paul-Gunther Sator has been an advisor and\/or received speaker honoraria or travel expense reimbursements and\/or received grants and\/or participated in clinical trials for AbbVie, Actelion, Amgen, Almirall, Janssen, Novartis, LEO Pharma, Pfizer, MSD, Celgene, Maruho, ALK, Galderma Abbott, UCB, Gilead, and Eli-Lilly. Ralph von Kiedrowski declares that, through his own company CMS GmbH, he has received honoraria for lectures, consultancy work, and studies from AbbVie, Almirall, Biofrontera, Biogen, Celgene, Dr. Pfleger, Foamix, Janssen Cilag, LEO Pharma, Lilly, Medac, MSD, Novartis, Pfizer, Tigercat, and UCB. Dimitris Rigopoulos has received consultancy fees, payment for lectures and support for travel to scientific meetings from Celgene, Novartis, Janssen, and AbbVie. Marco Romanelli has participated in the advisory board of AbbVie, Eli Lilly, Novartis, and Urgo. Pierre-Dominique Ghislain has received speaker fees, participated in clinical trials and\/or advisory boards for Pfizer, MSD, AbbVie, Janssen-Cilag, Merck-Serono, LEO Pharma, Novartis, UCB, Amgen, Eli Lilly, Galderma, BMS, Meda, Maruho, Flen, Menarini, Almirall, PellePharm, and Mylan. Tiago Torres has received speaker fees, participated in clinical trials and\/or advisory boards for AbbVie, Almirall, Amgen, Arena Pharmaceuticals, BIOCAD, Biogen, Boehringer Ingelheim, Bristol-Myers Squibb, Celgene, Janssen, LEO Pharma, Eli Lilly, MSD, Mylan, Novartis, Pfizer, Samsung-Bioepis, Sanofi-Genzyme, and Sandoz. Tiago Torres is an Editorial Board member of\n                      Dermatology and Therapy\n                      for Atopic Dermatitis. Tiago was not involved in the selection of peer reviewers for the manuscript nor any of the subsequent editorial decisions. Dimitrios Ioannides has received speaker fees, participated in clinical trials and\/or advisory boards for AbbVie, Eli Lilly, Genesis, Galderma, Janssen, LEO Pharma, Novartis, Pfizer, and UCB. Cynthia Vizcaya, Andreas Clemens, and Weibin Bao are employees and shareholders of Novartis. Christelle C. Pieterse is an employee of Syneos Health, Amsterdam, the Netherlands, contracting for Novartis. Barbara Schulz is an associate at GKM Gesellschaft fuer Therapieforschung mbH, Lessingstrasse, M\u00fcnchen, Germany, which provides services to Novartis. Piotr Jagiello was employed by Novartis at the time of the study. Curdin Conrad served as scientific advisor and\/or clinical study investigator and\/or paid speaker for AbbVie, Actelion, Almirall, Amgen, Boehringer Ingelheim, Bristol-Myers Squibb, Celgene, Galderma, Incyte, Janssen, LEO Pharma, Eli Lilly, MSD, Novartis, Pfizer, Samsung, and UCB.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of Interest"}},{"value":"All patients provided written informed consent before enrollment. The study protocol was approved by the institutional review board of each participating center according to local regulations. The trial is conducted in accordance with the Guidelines for Good Pharmacoepidemiology Practices (GPP) of the International Society for Pharmacoepidemiology (ISPE 2008), the Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) guidelines, the Declaration of Helsinki, and local regulations for each country.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical Approval"}}]}}